Bloomberg Law
Free Newsletter Sign Up
Login
BROWSE
Bloomberg Law
Welcome
Login
Advanced Search Go
Free Newsletter Sign Up

Lilly’s Retevmo Gets FDA OK for RET Fusion-Positive Solid Tumors

Sept. 21, 2022, 9:32 PM

Lilly’s Retevmo was granted accelerated approval by the US FDA for adult patients with locally advanced or metastatic solid tumors with a rearranged during transfection gene fusion that have progressed on or following prior systemic treatment or who have no satisfactory alternative treatment options.

  • Continued approval may be contingent upon verification of clinical benefit in confirmatory trials

To view the source of this information, click here

To contact the reporter on this story:
Greg Chang in San Francisco at gchang1@bloomberg.net

To contact the editor responsible for this story:
Chakradhar Adusumilli at cadusumilli@bloomberg.net

© 2022 Bloomberg L.P. All rights reserved. Used ...